← All trials
NCT05273944
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 28, 2021
- Primary completion
- Mar 31, 2022
- Completion date
- Apr 30, 2022
- First posted
- Mar 10, 2022
- Last posted
- Mar 10, 2022
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.Lead sponsor
- Central South UniversityCollaborator
- Chongqing Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Jinan UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Guangzhou Panyu Central HospitalCollaborator
- Yuebei People's HospitalCollaborator
- Guizhou Medical UniversityCollaborator
- Shantou UniversityCollaborator
- Yuncheng Central HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.